
Quarterly report 2025-Q3
added 11-14-2025
Greenwich LifeSciences Market Cap 2011-2026 | GLSI
As of March 03, 2026 Greenwich LifeSciences has a market cap of $ 360 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Greenwich LifeSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 M | 183 M | 170 M | 256 M | 330 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 330 M | 115 M | 211 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Alector
ALEC
|
247 M | $ 2.19 | -9.77 % | $ 226 M | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Cabaletta Bio
CABA
|
20.5 M | $ 3.34 | 0.45 % | $ 3.9 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Codexis
CDXS
|
291 M | $ 1.02 | 1.49 % | $ 74.9 M | ||
|
AbCellera Biologics
ABCL
|
962 M | $ 3.74 | 3.6 % | $ 1.12 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Cerus Corporation
CERS
|
301 M | $ 2.6 | 1.37 % | $ 480 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
Cellectis S.A.
CLLS
|
203 M | $ 3.87 | -0.39 % | $ 116 M | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
CNS Pharmaceuticals
CNSP
|
520 K | $ 3.23 | 2.22 % | $ 1.23 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Collegium Pharmaceutical
COLL
|
1.4 B | $ 41.75 | 0.19 % | $ 1.32 B | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
3.75 B | $ 36.14 | 1.23 % | $ 3.75 B | ||
|
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | ||
|
Amarin Corporation plc
AMRN
|
440 M | $ 13.98 | 1.27 % | $ 5.7 B | ||
|
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
3.04 B | $ 23.77 | 2.99 % | $ 2.91 B | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
45 M | $ 8.41 | -1.87 % | $ 36.4 M | ||
|
Cardiff Oncology
CRDF
|
116 M | $ 1.94 | 0.01 % | $ 130 M | ||
|
Curis
CRIS
|
13.2 M | $ 1.1 | -3.51 % | $ 6.94 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
CorMedix
CRMD
|
174 M | $ 7.16 | 0.42 % | $ 364 M | ||
|
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | ||
|
Champions Oncology
CSBR
|
106 M | $ 6.14 | 3.89 % | $ 83.9 M | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | ||
|
Citius Pharmaceuticals
CTXR
|
24.2 M | $ 0.72 | -2.34 % | $ 4.84 M | ||
|
Athira Pharma
ATHA
|
16.2 M | - | - | $ 269 M | ||
|
Aridis Pharmaceuticals
ARDS
|
4.13 M | - | 17.91 % | $ 11.1 M | ||
|
Altimmune
ALT
|
463 M | $ 4.21 | -2.32 % | $ 299 M | ||
|
CEL-SCI Corporation
CVM
|
26.2 M | $ 3.88 | -8.92 % | $ 247 M |